Home > Companies > Jigsaw Medical

Jigsaw Medical

jigsawmedical.com

Founded in 2012 by Chris Percival, Jigsaw Medical has quickly become one of the UK leaders in medical services, offering a range of services for the commercial, media, events sectors and the NHS. Jigsaw Medical is divided into three clear entities; our Clinical Services Division, Training Division, and our Specialist Projects Division. We are committed to delivering clinically focused and harmonised solutions to both NHS and private clients. Our Clinical Services Division specialises in providing ambulance services, event medical cover, and TV / Film unit medics whilst our Training Division provides first aid training courses and clinical education. Finally, our Special Projects Division provides specific medical training and medical staff for close protection, hostile, and remote environments – making up our four clear divisions.

C-Suite On Deck

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Events

RNA Therapeutics USA

Conference

4th Digital Congress on Nanobiotechnology and Bioengineering

Conference

Long-acting Delivery of Ocular Biotherapeutics

Webinar

19thEuropean Congress on Digital Pathology

Conference

3rd Edition of Euro-Global Conference on Biotechnology and Bioengineering

Conference

2023 ISPE Biotechnology Conference

Conference

Related News

CEDILLA THERAPEUTICS COMPLETES $82.6M SERIES B FINANCING

Cedilla Therapeutics | October 25, 2021

Cedilla Therapeutics a biotechnology company bringing a new dimension to precision oncology, today announced that it has raised an additional $25 million in an expansion of its Series B financing, bringing the total amount raised to $82.6 million. The oversubscribed Series B expansion includes new investors RA Capital Management, Janus Henderson Investors, Woodline Partners LP and Logos Capital, along with participation from existing investor Third Rock Ventures.“We are grateful for the su...

CELL AND GENE THERAPY

BIOCYTOGEN COMPLETES A NEW ROUND OF FINANCING TOTALING TENS OF MILLIONS OF DOLLARS

Biocytogen | June 23, 2021

Biocytogen, a worldwide biotechnology organization zeroed in on neutralizer drug innovative work (R&D) utilizing creative genetically designed creature models, today declared the fruitful culmination of another round of financing adding up to a huge number of dollars. The financing was together finished by Lake Bleu Capital, CPE, Octagon Capital and OrbiMed. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. was set up in 2009. Utilizing its primary quality altering innovation, th...

MEDTECH

HALO LABS LAUNCHES THE AURA GT™ FOR GENE THERAPY PRODUCT QUALITY

Halo Labs | October 05, 2021

Halo Labs, a life science instrumentation company developing tools for biologics researchers, today announced it has launched its latest product, Aura GT. Aura GT is part of the next generation in Halo Labs' popular family of instruments. Using Backgrounded Membrane Imaging (BMI) and Fluorescence Membrane Microscopy (FMM), Aura GT can distinguish aggregated capsids from contaminants, carrier proteins, and other particles that might adversely harm patients. Unique to Aura GT is...

CELL AND GENE THERAPY

SPOTLIGHT THERAPEUTICS CLOSES ITS SERIES A FINANCING BRINGING THE TOTAL RAISED TO $30 MILLION

Spotlight Therapeutics | December 01, 2020

Spotlight Therapeutics, Inc., a biotechnology organization creating non-viral quality altering therapeutics for direct in vivo altering of target genes, closed its Series A financing bringing the complete raised to $30 million. The financing was driven by GV, in the past Google Ventures, with interest from extra undisclosed investors. Realizing the full revolutionary potential of CRISPR genome editing requires the ability to edit target genes directly in the right cells of the hum...